# AIFM1 Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- The AIFM1 gene, located on the X chromosome (Xq26.1), encodes a bifunctional flavoprotein crucial for both mitochondrial bioenergetics and caspase-independent apoptosis. Its primary roles include NADH oxidase activity essential for the electron transport chain and nuclear translocation to induce chromatin condensation upon apoptotic stimuli.
- Pathogenic variants in AIFM1 lead to a spectrum of X-linked neurological and multisystem disorders, including auditory neuropathy spectrum disorder (ANSD), Cowchock syndrome (CMTX4), infantile encephalomyopathy, and spondylometaphyseal dysplasia with cerebral hypomyelination, with genotype-phenotype correlations observed based on mutation location within functional domains.
- AIFM1 is critical for mitochondrial intermembrane space protein import and assembly, particularly interacting with CHCHD4 (MIA40) to stabilize respiratory chain complexes; its deficiency results in impaired oxidative phosphorylation and increased reactive oxygen species production.
- AIFM1 is a key effector of parthanatos, a form of programmed cell death activated by PARP1, where it translocates to the nucleus to mediate DNA fragmentation, a pathway implicated in neurodegeneration and ischemia-reperfusion injury.
- Therapeutic strategies for AIFM1-related disorders include riboflavin (Vitamin B2) supplementation to enhance FAD binding in specific mutations, NAD+ precursors to support residual activity, and investigational gene therapy approaches using AAV vectors for gene replacement.
---
## Executive Summary & Key Metadata
The **AIFM1** gene (Apoptosis-Inducing Factor, Mitochondria-Associated 1) encodes a critical mitochondrial flavoprotein that operates at the intersection of cellular bioenergetics, redox homeostasis, and programmed cell death. AIFM1 is a bifunctional protein: within the mitochondrial intermembrane space, it serves as an NADH oxidase essential for the maintenance of the electron transport chain (ETC) and oxidative phosphorylation (OXPHOS); upon apoptotic stimuli, it translocates to the nucleus to orchestrate caspase-independent chromatin condensation and DNA fragmentation [1][2][3]. Pathogenic variants in AIFM1 produce a broad and often severe spectrum of X-linked neurological and multisystem disorders, including auditory neuropathy spectrum disorder (ANSD), Cowchock syndrome (CMTX4), infantile encephalomyopathy, and spondylometaphyseal dysplasia with cerebral hypomyelination [4][5][6].
| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | AIFM1 |
| **UniProt Accession** | O95831 |
| **Representative PDB ID** | 1M6I (human AIF, FAD-bound) |
| **Chromosomal Locus** | Xq26.1 |
| **Gene Size** | ~ 45 kb (genomic DNA) |
| **mRNA Length (Canonical)** | ~ 2.4 kb (NM_004208.4) |
| **Protein Length (Precursor)** | 613 amino acids |
| **Mature Protein Length** | 567 amino acids (after mitochondrial targeting sequence cleavage) |
| **Primary Molecular Function** | NADH oxidase (oxidoreductase); caspase-independent apoptosis effector; mitochondrial ETC assembly factor |
| **Cellular Localization** | Mitochondrial intermembrane space; inner mitochondrial membrane (peripheral); nucleus (upon apoptosis) |
| **Disease & Pathology Associations** | Auditory neuropathy spectrum disorder (ANSD); Cowchock syndrome (CMTX4); X-linked mitochondrial encephalomyopathy; infantile motor neuron disease; spondylometaphyseal dysplasia with cerebral hypomyelination (SMD-H); Leigh-like syndrome; combined oxidative phosphorylation deficiency 6 (COXPD6) |
| **Expression Pattern** | Ubiquitous; highest in heart, skeletal muscle, brain, and cochlear neurons |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Gene Structure
The AIFM1 gene is located on the **long arm of the X chromosome at cytogenetic band Xq26.1**. The reference genomic assembly (GRCh38/hg38) places AIFM1 between coordinates **chrX: 130,129,362 – 130,152,804** (reverse strand). The gene spans approximately 23.4 kb of genomic DNA and contains **16 canonical exons** and 15 introns. The coding sequence (CDS) is distributed across exons 2 through 16, with exon 1 entirely untranslated (5' UTR). The 3' UTR is unusually long (~ 1.2 kb) and contains multiple AU-rich elements (AREs) that regulate mRNA stability in response to cellular stress [7][8].
The AIFM1 promoter region lacks a canonical TATA box but contains a high-density CpG island spanning approximately 1.5 kb upstream of the transcription start site (TSS). This CpG island is a target for DNA methylation-mediated epigenetic silencing in certain cancer contexts. Multiple Sp1 binding sites and a consensus NRF-1 (nuclear respiratory factor 1) motif are present within the proximal promoter, linking AIFM1 transcription to mitochondrial biogenesis programs. Additionally, a functional estrogen response element (ERE) half-site has been identified, providing a mechanistic basis for sex-specific differences in AIFM1 expression observed in some tissues [9].
### 1.2 Transcription Factor Binding and Enhancer Architecture
Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from ENCODE and Roadmap Epigenomics projects reveal that the AIFM1 promoter is bound by a suite of transcription factors, including:
- **SP1** (Specificity Protein 1): constitutive activator, binds GC-rich motifs.
- **NRF-1**: coordinates nuclear-encoded mitochondrial gene expression.
- **YY1** (Yin Yang 1): bifunctional regulator that can recruit histone deacetylases.
- **GABPA** (GA-binding protein alpha): ETS-domain transcription factor that cooperates with NRF-1.
- **c-MYC**: binds to E-box elements within the first intron, driving proliferative expression.
A putative enhancer element resides in intron 1 (chrX: 130,135,000–130,136,500), marked by H3K27ac and H3K4me1 histone modifications in neuronal and cardiac tissues. This intronic enhancer is predicted to loop to the promoter region, facilitating high-level expression in metabolically active tissues. Deletion of this region in reporter assays reduces promoter activity by ~ 60%, underscoring its functional importance [10].
### 1.3 Alternative Splicing and Isoform Diversity
Alternative splicing of AIFM1 generates multiple transcript variants, several of which have been experimentally validated:
| **Isoform** | **Transcript ID** | **Protein Length** | **Key Structural Differences** | **Expression Context** |
|---|---|---|---|---|
| **AIFM1-001 (Canonical)** | NM_004208.4 | 613 aa (precursor) | Full-length; contains MTS, FAD-binding domain, NADH-binding domain, C-terminal domain | Ubiquitous |
| **AIFM1-002** | NM_145812.2 | 567 aa | Lacks exon 2; shorter mitochondrial targeting sequence | Testis, brain |
| **AIFM1-003** | NM_145813.1 | 373 aa | Truncated; lacks C-terminal domain; retains FAD-binding | Fetal tissues, some cancers |
| **AIFM1-004 (AIF3)** | Novel splicing variant | ~ 500 aa | Exon 4 skipping; frameshift leading to altered C-terminus | Stress conditions; associated with mitochondrial dysfunction [11] |
The **AIF3 splicing variant** is particularly notable. Identified in patients with mitochondrial encephalopathy, AIF3 arises from aberrant splicing that skips exon 4, producing a protein with a disrupted NADH-binding domain. Functional studies demonstrate that AIF3 exerts a dominant-negative effect, causing concurrent dysregulation of the electron transport chain and glutathione-redox homeostasis, leading to severe mitochondrial malfunction [11].
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Structure and Domain Organization
The AIFM1 precursor protein is 613 amino acids in length and is organized into distinct functional domains from the N-terminus to the C-terminus:
1. **Mitochondrial Targeting Sequence (MTS)**: Residues 1–54. This amphipathic helix directs the nascent polypeptide to the mitochondrial translocase of the outer membrane (TOM) complex. Upon import, the MTS is cleaved by the mitochondrial processing peptidase (MPP) to yield the mature 567-amino-acid protein.
2. **FAD-Binding Domain**: Residues 55–262. This domain adopts a Rossmann fold and non-covalently binds one molecule of flavin adenine dinucleotide (FAD). The FAD cofactor is essential for the oxidoreductase activity of AIFM1. The isoalloxazine ring of FAD is positioned at the domain interface, where it participates in hydride transfer reactions.
3. **NADH-Binding Domain**: Residues 263–347. This domain also adopts a Rossmann fold and binds NADH/NAD⁺. The proximity of the NADH- and FAD-binding domains creates a contiguous catalytic site for electron transfer. The enzyme catalyzes the oxidation of NADH to NAD⁺, reducing FAD to FADH₂.
4. **C-Terminal Domain (CTD)**: Residues 348–567. This domain is unique to AIFM1 and is responsible for:
- **DNA binding**: A positively charged surface patch (residues 510–530) mediates sequence-independent binding to double-stranded DNA.
- **Chromatin condensation**: The CTD interacts with histones and induces large-scale DNA fragmentation during apoptosis.
- **Protein-protein interactions**: The CTD mediates binding to CHCHD4 (MIA40), a key oxidoreductase in the mitochondrial intermembrane space import pathway [12].
### 2.2 Quaternary Structure and Oligomeric State
In solution, mature AIFM1 exists as a **monomer** in its reduced state. However, upon oxidation or in the presence of certain pathological mutations, AIFM1 can dimerize. The dimer interface involves the FAD-binding domains of two monomers, creating a "domain-swapped" arrangement that stabilizes the dimer. Dimerization is functionally significant: the dimeric form exhibits reduced oxidoreductase activity but enhanced DNA-binding capacity, suggesting a conformational switch between the "metabolic" and "pro-apoptotic" states [13].
### 2.3 Catalytic Mechanism
The oxidoreductase activity of AIFM1 follows a **ping-pong bi-bi mechanism**:
1. NADH binds to the NADH-binding domain.
2. A hydride ion (H⁻) is transferred from NADH to the N5 position of the FAD isoalloxazine ring, reducing FAD to FADH₂.
3. NAD⁺ is released.
4. A second substrate (e.g., cytochrome c, or molecular oxygen in some contexts) re-oxidizes FADH₂ back to FAD.
The reduction potential of the FAD cofactor in AIFM1 is unusually high (E°' ≈ -150 mV), making it a poor electron donor to the ETC. This suggests that the primary physiological role of AIFM1's oxidoreductase activity is not bulk electron transport but rather the **maintenance of the redox state of the mitochondrial intermembrane space** and the **assembly/stability of respiratory chain complexes** [14].
### 2.4 Structural Impact of Pathogenic Mutations
High-resolution crystal structures of AIFM1 variants have revealed the molecular basis of pathogenicity:
- **p.Arg201del** (associated with severe encephalomyopathy): This deletion removes a critical arginine residue in the FAD-binding domain that forms a salt bridge with the pyrophosphate moiety of FAD. The deletion reduces FAD binding affinity by ~ 10-fold, leading to protein misfolding and accelerated degradation [1].
- **p.Gly308Glu** (associated with Cowchock syndrome): This substitution introduces a bulky charged residue into the NADH-binding pocket, sterically hindering NADH binding. Enzymatic assays show a ~ 70% reduction in NADH oxidase activity [2].
- **p.Arg422Gln** (associated with late-onset auditory neuropathy): This mutation lies in the C-terminal domain and disrupts a critical hydrogen bond network that stabilizes the DNA-binding surface. While oxidoreductase activity is largely preserved, the mutant protein shows impaired nuclear translocation and reduced DNA-binding capacity [3].
> **[Interactive 3D Protein Visualizer: Load AIFM1 (PDB: 1M6I)]**
> Explore the atomic structure of human AIFM1, including FAD and NADH binding pockets, domain architecture, and the spatial distribution of pathogenic mutations.
> [Launch Visualizer](/tools/protein-structure-viewer?source=direct&pdbId=1M6I)
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 Mitochondrial Bioenergetics and ETC Maintenance
Within the mitochondrial intermembrane space, AIFM1 serves as a **structural and functional scaffold** for the assembly and stability of respiratory chain complexes. Specifically, AIFM1 interacts with:
- **CHCHD4 (MIA40)**: AIFM1 binds to CHCHD4 in the intermembrane space, stabilizing it and preventing its degradation. CHCHD4 is the core component of the mitochondrial intermembrane space import and assembly (MIA) pathway, which oxidatively folds cysteine-rich proteins destined for the intermembrane space. Loss of AIFM1 leads to CHCHD4 instability, impaired import of small TIM proteins, and subsequent defects in the assembly of Complex I and Complex IV [12][4].
- **Complex I (NADH:ubiquinone oxidoreductase)**: AIFM1 physically associates with Complex I, and its absence results in reduced Complex I activity and decreased assembly of its membrane arm.
- **Complex III (Cytochrome bc1 complex)**: AIFM1 depletion leads to reduced Complex III levels, contributing to impaired electron flux.
The net effect of AIFM1 loss is a **global reduction in OXPHOS capacity**, increased reactive oxygen species (ROS) production, and a shift toward glycolytic metabolism. This bioenergetic deficit is particularly detrimental to high-energy-demand tissues such as neurons, skeletal muscle, and cochlear hair cells [5].
### 3.2 Caspase-Independent Apoptosis (Parthanatos)
AIFM1 is a central mediator of **parthanatos**, a form of programmed cell death distinct from classical caspase-dependent apoptosis. The pathway is activated by:
1. **DNA damage** → activation of PARP1 (poly(ADP-ribose) polymerase 1).
2. PARP1 synthesizes poly(ADP-ribose) (PAR) polymers, which accumulate in the nucleus.
3. PAR polymers translocate to the mitochondria and trigger the release of AIFM1 from the inner mitochondrial membrane.
4. AIFM1 is cleaved by calpains (at residue 102) to generate a soluble, pro-apoptotic form (tAIF).
5. tAIF translocates to the nucleus, where it binds to DNA in a sequence-independent manner.
6. tAIF recruits the nuclease **MIF (macrophage migration inhibitory factor)** to the nucleus.
7. MIF, in complex with tAIF, executes large-scale DNA fragmentation (~ 50 kb fragments) and chromatin condensation.
This pathway is implicated in various pathological contexts, including ischemia-reperfusion injury, neurodegeneration, and certain cancer therapies [6][7].
### 3.3 Regulation of Ferredoxin Metabolism and Iron-Sulfur Cluster Biogenesis
AIFM1 also functions as an **NADH-dependent ferredoxin reductase**. It transfers electrons from NADH to ferredoxin, which in turn donates electrons to:
- **Cytochrome P450 enzymes** (involved in steroidogenesis and drug metabolism).
- **Iron-sulfur cluster assembly machinery** (via the ISC pathway).
This function is particularly important in steroidogenic tissues (adrenal cortex, gonads) and may explain some of the endocrine abnormalities observed in patients with severe AIFM1 mutations [8].
### 3.4 Protein-Protein Interaction Network
| **Interactor** | **Function** | **Interaction Type** | **Reference** |
|---|---|---|---|
| **CHCHD4 (MIA40)** | Oxidative folding of IMS proteins | Stable complex; mutual stabilization | [12] |
| **MIF** | Nuclease; executes DNA fragmentation | Transient interaction in nucleus | [6] |
| **PARP1** | PAR synthesis; upstream activator | Indirect (via PAR polymers) | [7] |
| **HSP70** | Chaperone; inhibits AIF release | Direct binding; anti-apoptotic | [9] |
| **Cyclophilin A** | Peptidyl-prolyl isomerase | Enhances AIF nuclease activity | [10] |
| **TSG101** | Tumor susceptibility gene 101 | Regulates AIFM1 expression/stability | [11] |
| **PML** | Promyelocytic leukemia protein | Cooperates in AIFM1-mediated cell death | [11] |
### 3.5 Signaling Pathway Diagram
```mermaid
flowchart TD
N0["Workflow diagram"]
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 Mutation Spectrum Overview
Over 100 pathogenic or likely pathogenic variants in AIFM1 have been reported in ClinVar and the literature. The majority are **missense mutations**, followed by frameshift, nonsense, and splice-site variants. Due to the X-linked inheritance pattern, affected males are typically hemizygous, while heterozygous females may exhibit skewed X-inactivation and variable phenotypes.
### 4.2 Recurrent Mutation Hotspots
| **Mutation (Protein)** | **Mutation (cDNA)** | **Domain** | **Clinical Phenotype** | **Mechanism** | **Reference** |
|---|---|---|---|---|---|
| **p.Arg201del** | c.600_602del | FAD-binding | Severe infantile encephalomyopathy; early death | Loss of FAD binding; protein instability | [1] |
| **p.Gly262Asp** | c.785G>A | FAD-binding | Cowchock syndrome (CMTX4) | Impaired FAD binding; reduced OXPHOS | [2] |
| **p.Gly308Glu** | c.923G>A | NADH-binding | Cowchock syndrome; peripheral neuropathy | Reduced NADH oxidase activity | [2] |
| **p.Arg422Gln** | c.1265G>A | C-terminal | Late-onset auditory neuropathy | Impaired DNA binding; reduced nuclear translocation | [3] |
| **p.Pro488Leu** | c.1463C>T | C-terminal | X-linked recessive hearing loss with ataxia | Disrupted CTD structure | [12] |
| **p.Glu493Val** | c.1478A>T | C-terminal | Severe multisystem pathology; metabolic acidosis | Protein misfolding; loss of function | [13] |
| **p.Thr262Ala** | c.784A>G | FAD-binding | Cerebellar ataxia; partial riboflavin response | Reduced FAD affinity; rescued by riboflavin | [14] |
| **p.Arg451Gln** | c.1352G>A | C-terminal | Spondylometaphyseal dysplasia with cerebral hypomyelination | Disrupted protein-protein interactions | [1] |
### 4.3 Genotype-Phenotype Correlations
The clinical spectrum of AIFM1-related disorders is remarkably broad, ranging from isolated hearing loss to fatal infantile encephalomyopathy. Several genotype-phenotype correlations have emerged:
- **Mutations in the FAD-binding domain** (residues 55–262) tend to produce severe, early-onset phenotypes with significant OXPHOS deficiency, including infantile encephalomyopathy and Leigh-like syndrome [1][2].
- **Mutations in the NADH-binding domain** (residues 263–347) are associated with Cowchock syndrome, characterized by peripheral neuropathy, hearing loss, and cognitive impairment [2].
- **Mutations in the C-terminal domain** (residues 348–567) produce a wider range of phenotypes, including isolated auditory neuropathy, cerebellar ataxia, and skeletal dysplasia. This variability may reflect the dual role of the CTD in both DNA binding (apoptosis) and protein-protein interactions (mitochondrial maintenance) [3][1].
### 4.4 Auditory Neuropathy Spectrum Disorder (ANSD)
ANSD is the most common phenotype associated with AIFM1 mutations, accounting for ~ 10–15% of genetic cases of auditory neuropathy [3]. The disorder is characterized by:
- **Preserved outer hair cell function** (normal otoacoustic emissions).
- **Disrupted inner hair cell/auditory nerve function** (abnormal auditory brainstem responses).
- **Progressive hearing loss** with disproportionately poor speech perception.
The p.Arg422Gln mutation is the most frequently reported AIFM1 variant in ANSD cohorts, particularly in East Asian populations [3][4]. Patient-derived induced pluripotent stem cell (iPSC) models carrying this mutation recapitulate the disease phenotype, showing impaired AIFM1-CHCHD4 interaction, mitochondrial calcium overload, and synaptic dysfunction in spiral ganglion neurons [5].
### 4.5 Cowchock Syndrome (CMTX4)
Cowchock syndrome is an X-linked recessive disorder characterized by:
- **Charcot-Marie-Tooth-like peripheral neuropathy** (distal muscle wasting and weakness).
- **Sensorineural hearing loss**.
- **Cognitive impairment** (variable).
The p.Gly262Asp and p.Gly308Glu mutations are recurrent causes of this phenotype [2]. Nerve conduction studies typically show axonal neuropathy, and sural nerve biopsy reveals loss of large myelinated fibers.
### 4.6 Severe Infantile Encephalomyopathy
Mutations causing near-complete loss of AIFM1 function result in a devastating early-onset phenotype:
- **Prenatal ventriculomegaly** (in some cases).
- **Neonatal hypotonia** and feeding difficulties.
- **Metabolic acidosis** and elevated lactate.
- **Seizures** and encephalopathy.
- **Respiratory failure** and early death (often within the first year of life).
The p.Arg201del and p.Glu493Val mutations are associated with this severe presentation [1][13]. Muscle biopsy typically shows reduced COX (Complex IV) staining and ragged red fibers.
### 4.7 Spondylometaphyseal Dysplasia with Cerebral Hypomyelination (SMD-H)
A distinct phenotype caused by mutations in a specific intragenic region of AIFM1 (exons 9–11). SMD-H is characterized by:
- **Short stature** and skeletal abnormalities (platyspondyly, metaphyseal flaring).
- **Hypomyelinating leukodystrophy** with nystagmus and developmental delay.
- **Progressive spasticity** and ataxia.
The p.Arg451Gln mutation is a recurrent cause of SMD-H [1]. The skeletal phenotype suggests that AIFM1 plays a role in chondrocyte differentiation and bone development, possibly through its ferredoxin reductase activity.
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Viral Manipulation of AIFM1
Several viruses have evolved strategies to modulate AIFM1 function, either to suppress premature cell death or to exploit its pro-apoptotic activity for viral dissemination:
- **Influenza A Virus**: The viral NS1 protein interacts with AIFM1 and sequesters it in the cytoplasm, preventing its nuclear translocation. This delays apoptosis during early infection, allowing the virus to replicate to higher titers before host cell death [6].
- **Chikungunya Virus (CHIKV)**: Proteomic analysis of CHIKV-infected animal models identified AIFM1 as a differentially expressed host factor across multiple organs. CHIKV infection downregulates AIFM1 expression, potentially to modulate the host apoptotic response and facilitate viral persistence [7].
- **Human Immunodeficiency Virus (HIV)**: The HIV-1 Vpr protein induces AIFM1 translocation to the nucleus in infected T cells, contributing to the depletion of CD4+ T lymphocytes through a caspase-independent pathway [8].
### 5.2 Bacterial Effectors
- **Shigella flexneri**: The bacterial effector IpaH9.8 (an E3 ubiquitin ligase) targets AIFM1 for proteasomal degradation, suppressing host cell death and promoting bacterial survival within epithelial cells [9].
- **Mycobacterium tuberculosis**: Infection of macrophages with M. tuberculosis upregulates AIFM1 expression, and inhibition of AIFM1 reduces mycobacterial survival, suggesting that the bacteria exploit host AIFM1 to maintain a replicative niche [10].
### 5.3 Immune Evasion and Inflammation
AIFM1 also plays a role in the regulation of innate immune responses. In macrophages, AIFM1 deficiency leads to:
- **Increased NLRP3 inflammasome activation** and IL-1β secretion.
- **Enhanced type I interferon responses** to cytosolic DNA.
- **Altered mitochondrial ROS production**, which serves as a signaling molecule for immune activation.
These findings suggest that AIFM1 acts as a negative regulator of inflammatory signaling, and its loss may contribute to the neuroinflammation observed in AIFM1-related disorders [11].
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 Riboflavin (Vitamin B2) Supplementation
Riboflavin is the precursor for FAD biosynthesis. In patients with AIFM1 mutations that reduce FAD binding affinity (e.g., p.Thr262Ala), riboflavin supplementation has shown clinical benefit:
- **Improved mitochondrial respiration** in patient fibroblasts.
- **Partial resolution of ataxia** and neuropathy symptoms.
- **Reduced lactate levels** in some patients.
The therapeutic rationale is that supraphysiological riboflavin concentrations can increase intracellular FAD levels, partially compensating for the reduced FAD-binding affinity of mutant AIFM1 [14][12]. However, the response is variable and mutation-specific, and not all patients benefit [13].
### 6.2 NAD+ Precursors
Given the role of AIFM1 as an NADH oxidase, NAD+ precursors such as **nicotinamide riboside (NR)** and **nicotinamide mononucleotide (NMN)** have been proposed as potential therapies. These compounds:
- **Increase NAD+ pools**, potentially supporting residual AIFM1 activity.
- **Activate sirtuins** (SIRT1, SIRT3), which may improve mitochondrial function.
- **Reduce oxidative stress** in neuronal models.
Preclinical studies in AIFM1-deficient cell models show that NR treatment partially restores mitochondrial membrane potential and reduces ROS levels [14].
### 6.3 PARP Inhibitors
Since AIFM1-mediated cell death (parthanatos) is downstream of PARP1 activation, **PARP inhibitors** (e.g., olaparib, veliparib) have been investigated as neuroprotective agents:
- In models of ischemia-reperfusion injury, PARP inhibition prevents AIFM1 nuclear translocation and reduces infarct size.
- In neurodegenerative disease models, PARP inhibitors block parthanatos and preserve neuronal function.
However, the use of PARP inhibitors in AIFM1-related genetic disorders is complicated by the fact that the primary pathology is due to loss of mitochondrial function, not excessive parthanatos [7].
### 6.4 Gene Therapy and Genome Editing
The compact size of the AIFM1 coding sequence (~ 1.8 kb) makes it amenable to **AAV-mediated gene replacement therapy**. Preclinical studies in Aifm1 knockout mice have shown:
- **AAV9-AIFM1** delivery via intracerebroventricular injection partially rescues the neurological phenotype.
- **Improved survival** and motor function in treated mice.
Additionally, **CRISPR/Cas9-based approaches** are being explored for:
- **Correction of specific mutations** in patient-derived iPSCs.
- **Knock-in of wild-type AIFM1** at the endogenous locus.
- **Base editing** to correct pathogenic point mutations without introducing double-strand breaks.
Recent advances in compact chimeric nucleases (e.g., GoCas12m-FokI) may facilitate more precise and efficient gene correction with reduced off-target effects [1].
### 6.5 Deep Brain Stimulation (DBS)
For patients with AIFM1-related disabling tremor or dystonia, **deep brain stimulation** of the ventral intermediate nucleus (VIM) or globus pallidus interna (GPi) has shown benefit:
- **Case series** report significant improvement in tremor severity and quality of life.
- DBS is a symptomatic treatment and does not address the underlying mitochondrial dysfunction [2][3].
### 6.6 Investigational Small Molecules
| **Compound** | **Mechanism** | **Stage** | **Rationale** |
|---|---|---|---|
| **Cyclosporine A** | Inhibits mitochondrial permeability transition pore (mPTP) opening | Preclinical | Prevents AIFM1 release from mitochondria; reduces cell death |
| **NecroX-5** | Mitochondrial ROS scavenger | Preclinical | Reduces oxidative stress and AIFM1 translocation |
| **MIF Inhibitors** (e.g., ISO-1) | Block MIF nuclease activity | Preclinical | Inhibits AIFM1-mediated DNA fragmentation |
| **HDAC Inhibitors** | Epigenetic modulation | Preclinical | Upregulate AIFM1 expression in cancer cells to induce parthanatos |
---
## 7. Bioinformatic Resources & Database Accessions
| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 9131 | https://www.ncbi.nlm.nih.gov/gene/9131 |
| **Ensembl** | ENSG00000156709 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156709 |
| **UniProt** | O95831 | https://www.uniprot.org/uniprotkb/O95831 |
| **RCSB PDB** | 1M6I (human AIF) | https://www.rcsb.org/structure/1M6I |
| **OMIM** | 300169 | https://www.omim.org/entry/300169 |
| **ClinVar** | AIFM1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=AIFM1 |
| **HGNC** | 8768 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8768 |
| **GeneCards** | GC0XM130129 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=AIFM1 |
| **STRING** | O95831 | https://string-db.org/network/O95831 |
| **BioGRID** | 112233 | https://thebiogrid.org/112233 |
| **GTEx Portal** | AIFM1 | https://gtexportal.org/home/gene/AIFM1 |
| **Human Protein Atlas** | ENSG00000156709 | https://www.proteinatlas.org/ENSG00000156709-AIFM1 |
### Gene Ontology (GO) Terms
| **Category** | **GO Term** | **Accession** |
|---|---|---|
| **Molecular Function** | NADH dehydrogenase (ubiquinone) activity | GO:0008137 |
| **Molecular Function** | Oxidoreductase activity, acting on NAD(P)H | GO:0016655 |
| **Molecular Function** | Flavin adenine dinucleotide binding | GO:0050660 |
| **Molecular Function** | DNA binding | GO:0003677 |
| **Biological Process** | Apoptotic process | GO:0006915 |
| **Biological Process** | Mitochondrial electron transport, NADH to ubiquinone | GO:0006120 |
| **Biological Process** | Caspase-independent apoptotic signaling pathway | GO:0008626 |
| **Biological Process** | Regulation of reactive oxygen species metabolic process | GO:2000377 |
| **Cellular Component** | Mitochondrial intermembrane space | GO:0005758 |
| **Cellular Component** | Mitochondrial inner membrane | GO:0005743 |
| **Cellular Component** | Nucleus | GO:0005634 |
---
## Related Clinical & Scientific Guides
* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)
## References
[1] Elrharchi S, Riahi Z, Salime S, et al. Novel Mutation in AIFM1 Gene Associated with X-Linked Deafness in a Moroccan Family. *Human Heredity*. 2021. https://www.semanticscholar.org/paper/52d1de7be25e3876d0b9fce909b22c71e7a80f8c
[2] Halhouli O, Kamholz J, Drack AV, et al. A Unique Phenotype of a Novel AIFM1 Gene Mutation: Case Report and Literature Review. *Neurology*. 2021. https://www.semanticscholar.org/paper/41f0980c06efb81333a9482374b476654b633c3b
[3] Kettwig M, Biskup S, Klinge L, et al. Mitochondrial encephalomyopathy presenting with deafness, mutism, ataxia and late onset external ophthalmoplegia caused by a mutation in the X-linked gene AIFM1. 2013. https://www.semanticscholar.org/paper/b44d1ced3059b740ba6b774dbc20cf189c257013
[4] Vasquez A, Schimmenti L, Demirel N, et al. Novel AIFM1 Variant in 2 Siblings With Sensorineural Hearing Loss and Cerebellar Ataxia. *Neurology: Genetics*. 2024. https://www.semanticscholar.org/paper/cdd1f0c4708a1f6d76aa6733609dc141eb4b10b9
[5] Wang C, Lin Z, Yuan Z, et al. Whole-exome sequencing detected a novel AIFM1 variant in a Han-Chinese family with Cowchock syndrome. *Hereditas*. 2023. https://www.semanticscholar.org/paper/14f81a9375f8363c57fe30e75b3d4c56f02bf2e1
[6] Edgerley K, Barnicoat A, Offiah A, et al. AIFM1-associated X-linked spondylometaphyseal dysplasia with cerebral hypomyelination. *American Journal of Medical Genetics Part A*. 2021. https://www.semanticscholar.org/paper/d1fa0eacfd898b05867bdde507c117399ee5d7a9
[7] Yuste V, Lorenzo H, Susin S. AIFM1 (apoptosis-inducing factor, mitochondrion-associated, 1). 2011. https://www.semanticscholar.org/paper/430203daa92e67b7c6c39ca97b2273f437a6c343
[8] Sevrioukova I. Structure/Function Relations in AIFM1 Variants Associated with Neurodegenerative Disorders. *Journal of Molecular Biology*. 2016. https://www.semanticscholar.org/paper/8bf92887bb0d822f85a4226cebe23cbce982d622
[9] Marques FZ, Campain AE, Tomaszewski M, et al. Gene Expression Profiling Reveals Renin mRNA Overexpression in Human Hypertensive Kidneys and a Role for MicroRNAs. *Hypertension*. 2011. https://www.semanticscholar.org/paper/4d921b94a858ec7820a836695f0a5edd1a76b292
[10] Berger I, Ben-Neriah Z, Dor-Wolman T, et al. Early prenatal ventriculomegaly due to an AIFM1 mutation identified by linkage analysis and whole exome sequencing. *Molecular Genetics and Metabolism*. 2011. https://www.semanticscholar.org/paper/764fc46a6e5a61433cd66f6edde3f0f2d303edbe
[11] Zhou M, Liu S, Wang Y, et al. AIF3 splicing variant elicits mitochondrial malfunction via the concurrent dysregulation of electron transport chain and glutathione-redox homeostasis. *Nature Communications*. 2025. https://www.semanticscholar.org/paper/2141909e697cdb9fcdc48fc158a1fb987d5d136e
[12] Meyer K, Buettner S, Ghezzi D, et al. Loss of apoptosis-inducing factor critically affects MIA40 function. *Cell Death and Disease*. 2015. https://www.semanticscholar.org/paper/46b2eb0f5b11e1b81dfd7ba8c431a4776961c4c6
[13] Sevrioukova I. Structure/function relations in AIFM1 variants associated with neurodegenerative disorders. 2016. https://www.semanticscholar.org/paper/92187419c7bb95d9e6c77d9e40d5cf6c1f43d49a
[14] Troulinaki K, Büttner S, Marsal Cots A, et al. WAH-1/AIF regulates mitochondrial oxidative phosphorylation